A novel INS mutation in a family with maturity-onset diabetes of the young: Variable insulin secretion and putative mechanisms.
Stephanie R JohnsonIvan McGownUdo OppermannLouise S ConwellMark HarrisEmma L DuncanPublished in: Pediatric diabetes (2018)
Insulin gene (INS) mutations cause a rare form of maturity-onset diabetes of the young (MODY), a heterogeneous group of autosomal dominant diabetes with at least 14 confirmed causative genes. Here, we describe a family with MODY due to a novel INS mutation, detected using massively parallel sequencing (MPS). The proband presented aged 11 years with mild diabetic ketoacidosis. She was negative for IA2 and GAD antibodies. She had a strong family history of diabetes affecting both her two siblings and her mother, none of whom had ketosis but who were considered to have type 1 diabetes and managed on insulin, and her maternal grandfather, who was managed for decades on sulfonylureas. Of note, her younger sister had insulin deficiency but an elevated fasting proinsulin:insulin ratio of 76% (ref 5%-30%). Sanger sequencing of HNF4A, HNF1A, and HNF1B in the proband was negative. Targeted MPS using a custom-designed amplicon panel sequenced on an Illumina MiSeq detected a heterozygous INS mutation c.277G>A (p.Glu93Lys). Sanger sequencing confirmed the variant segregated with diabetes within the family. Structural analysis of this variant suggested disruption of a critical hydrogen bond between insulin and the insulin receptor; however, the clinical picture in some individuals also suggested abnormal insulin processing and insulin deficiency. This family has a novel INS mutation and demonstrated variable insulin deficiency. MPS represents an efficient method of MODY diagnosis in families with rarer gene mutations.
Keyphrases
- type diabetes
- glycemic control
- blood glucose
- cardiovascular disease
- insulin resistance
- dna methylation
- gene expression
- pregnant women
- early onset
- blood pressure
- immune response
- genome wide
- inflammatory response
- toll like receptor
- autism spectrum disorder
- skeletal muscle
- metabolic syndrome
- transcription factor
- replacement therapy
- drug delivery
- cancer therapy